Vivoryon Therapeutics AG(NL:VVY)
€0.76-0.01 (-1.56%)
NL:VVY
Vivoryon Therapeutics AG stock drug pipeline
€0.76
At close:-0.01 (-1.56%)
Want to see NL:VVY full AI Analyst Report?
Vivoryon Therapeutics AG (VVY) Drug Pipeline
2 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Pq912 | Alzheimer Disease | Phase II | Terminated | A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD | Apr 15, 2019 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Pq912 | Phase II | Alzheimer Disease | Terminated | A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD | Apr 15, 2019 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Vivoryon Therapeutics AG (NL:VVY) have in its pipeline
Vivoryon Therapeutics AG NL:VVY is currently developing the following drugs: Pq912. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
